Equities analysts forecast that Mersana Therapeutics Inc (NASDAQ:MRSN) will post earnings per share of ($0.38) for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for Mersana Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.36) and the lowest estimate coming in at ($0.41). Mersana Therapeutics posted earnings of ($0.97) per share in the same quarter last year, which indicates a positive year over year growth rate of 60.8%. The firm is scheduled to issue its next quarterly earnings results on Friday, March 13th.
According to Zacks, analysts expect that Mersana Therapeutics will report full-year earnings of ($0.59) per share for the current fiscal year, with EPS estimates ranging from ($0.72) to ($0.38). For the next year, analysts forecast that the business will report earnings of ($1.42) per share, with EPS estimates ranging from ($1.84) to ($1.21). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side analysts that that provide coverage for Mersana Therapeutics.
Mersana Therapeutics (NASDAQ:MRSN) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.35) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.02. Mersana Therapeutics had a negative return on equity of 41.14% and a negative net margin of 79.49%. The business had revenue of $0.84 million for the quarter, compared to analysts’ expectations of $0.50 million.
MRSN stock traded up $0.08 during midday trading on Monday, hitting $4.24. 495,890 shares of the stock were exchanged, compared to its average volume of 246,434. The stock’s 50-day moving average price is $2.58 and its 200-day moving average price is $3.03. The stock has a market cap of $203.03 million, a price-to-earnings ratio of -1.52 and a beta of 2.09. Mersana Therapeutics has a fifty-two week low of $1.32 and a fifty-two week high of $7.65. The company has a debt-to-equity ratio of 0.06, a quick ratio of 5.12 and a current ratio of 5.12.
Several hedge funds and other institutional investors have recently made changes to their positions in MRSN. Marshall Wace LLP acquired a new stake in Mersana Therapeutics during the 1st quarter valued at $141,000. Acadian Asset Management LLC acquired a new position in shares of Mersana Therapeutics in the second quarter worth $204,000. Russell Investments Group Ltd. lifted its position in shares of Mersana Therapeutics by 41.8% in the second quarter. Russell Investments Group Ltd. now owns 13,900 shares of the company’s stock valued at $56,000 after acquiring an additional 4,100 shares in the last quarter. Panagora Asset Management Inc. purchased a new stake in shares of Mersana Therapeutics in the second quarter valued at $397,000. Finally, Charles Schwab Investment Management Inc. boosted its stake in shares of Mersana Therapeutics by 144.0% during the second quarter. Charles Schwab Investment Management Inc. now owns 85,045 shares of the company’s stock valued at $345,000 after acquiring an additional 50,195 shares during the last quarter. 80.37% of the stock is currently owned by institutional investors.
Mersana Therapeutics Company Profile
Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company focusing on the development of antibody drug conjugate (ADC) for cancer patients with unmet need. The company develops Dolaflexin, a platform, which is used to generate a pipeline of proprietary ADC product candidates to address patient populations that are not amenable to treat with traditional ADC-based therapies.
Featured Article: Technical Indicators – What is a Golden Cross?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mersana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mersana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.